Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07469891) titled 'A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Prelude Therapeutics
Condition:
Polycythemia Vera (PV)
Myelofibrosis (MF)
Myeloproliferative Neoplasms (MPNs)
Post-Polycythemia Vera Myelofibrosis
Post-Essential Thrombocythemia Myelofibrosis
Primary Myelofibrosis (PMF)
Intervention:
Drug: PRT12396
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: Apri...